Abstract
M6620 is a highly potent and selective ATP-competitive ATR inhibitor. It showed strong synergy with cisplatin and radiation in preclinical cancer models. The significant vulnerability to ATR inhibition by cancer cells harboring inactivating p53 mutations provided a rationale to test the safety of M6620 along with definitive chemoradiation in Head and Neck Squamous Cell Carcinoma (HNSCC) where such alterations are common.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
